Jomezadeh Mina, Zamani-Alavijeh Fereshteh, Aleebrahim Forugh, Nasirian Maryam
Student Research Committee, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Health Education and Promotion, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
PLOS Glob Public Health. 2023 Mar 7;3(3):e0000689. doi: 10.1371/journal.pgph.0000689. eCollection 2023.
This study aimed to investigate the effect of role-playing and lecture on improving the attitudes of the Khorramabad suburban population toward the human immunodeficiency virus (HIV). In 2019, 270 people aged 18 and above participated in a randomized controlled trial in Khorramabad, Iran. Individuals were randomly assigned to one of three groups: role-playing, lecture, or control. To collect data before and after the intervention, we used a standard HIV knowledge and attitude questionnaire. Before the educational intervention, three marginalized groups' attitudes toward HIV were stigmatized. After the intervention, the attitudes of both the role-playing and lecture groups improved significantly relative to the control group (P<0.0001); there was no significant difference between the two methods (P>0.05). The correlation between attitude and knowledge scores was positive (P<0.0001). This study demonstrates that education is a fundamental pillar of improving attitudes toward people living with HIV (PLHIV) and can reduce stigma against them, thereby increasing their desire to disclose their condition and seek medical care. Trial registration: The trial registration code is IRCTID: IRCT20190807044467N1 (https://en.irct.ir/trial/41464).
本研究旨在调查角色扮演和讲座对改善霍拉马巴德郊区人口对人类免疫缺陷病毒(HIV)态度的影响。2019年,270名18岁及以上的人参与了伊朗霍拉马巴德的一项随机对照试验。个体被随机分配到三组之一:角色扮演组、讲座组或对照组。为了在干预前后收集数据,我们使用了一份标准的HIV知识和态度问卷。在教育干预之前,三个边缘化群体对HIV的态度存在污名化。干预后,与对照组相比,角色扮演组和讲座组的态度均有显著改善(P<0.0001);两种方法之间无显著差异(P>0.05)。态度得分与知识得分之间的相关性为正(P<0.0001)。本研究表明,教育是改善对HIV感染者(PLHIV)态度的基本支柱,可减少对他们的污名化,从而增加他们披露病情并寻求医疗护理的意愿。试验注册:试验注册号为IRCTID: IRCT20190807044467N1(https://en.irct.ir/trial/41464)。